Study suggests new anti-KRAS drug as a strong candidate for

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine's Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials.

Related Keywords

United States , American , Ben Stanger , Robert Vonderheide , Emily Henderson , Penn Medicine Abramson Cancer Center , Perelman School Of Medicine , Abramson Cancer Center , Penn Pancreatic Cancer Research Center , American Association For Cancer Research , University Of Pennsylvania , Johnh Glick Abramson Cancer Center Professor , Hanna Wise Professor In Cancer Research , Penn Medicine , Cancer Discovery , American Association , Hanna Wise Professor , Cancer Research , Perelman School , Penn Pancreatic Cancer Research , Mirati Therapeutics , Discovery Industry Focus , Abramson Cancer Center Professor , Cancer , Pancreatic Cancer , Fell , Drugs , Gene , Immune System , Immunotherapy , Medicine , Olecule , Utation , Reclinical , Research , Humor ,